Sihuan Pharmaceutical announced results for the six months ended June 30, 2026. The group achieved total revenue of 1,161 million yuan during the period, an increase of 1.3% over the previous year; profit attributable to company owners was 225 million yuan, an increase of 119% over the previous year; and a basic profit of 2.49 points per share. According to the announcement, changes in earnings are mainly driven by the medical, aesthetic and innovative drug businesses. During the period, revenue from the medical and aesthetic business was approximately RMB 693 million, an increase of about 18.5% over the previous year. The medical and aesthetic business has maintained steady development. The Group's medical and aesthetic sector continues to benefit from the steady growth of the core product Lotivo® and the continued release of regenerative medical and aesthetic products and functional medical and aesthetic products, driving related business revenue growth, and the medical and aesthetic business continues to be an important source of profit for the Group. Revenue from innovative drugs and other pharmaceuticals was approximately RMB 261 million, up about 349.1% year over year. The commercialization process of the innovative drug business continues to advance. The commercialization and internationalization of various approved products progressed well, and consolidated revenue ushered in a significant increase. Compared with the net loss of the previous period, net profit for the current period increased slightly.

Sihuan Pharmaceutical announced results for the six months ended June 30, 2026. The group achieved total revenue of 1,161 million yuan during the period, an increase of 1.3% over the previous year; profit attributable to company owners was 225 million yuan, an increase of 119% over the previous year; and a basic profit of 2.49 points per share. According to the announcement, changes in earnings are mainly driven by the medical, aesthetic and innovative drug businesses. During the period, the revenue from the medical and aesthetic business was approximately RMB 693 million, an increase of about 18.5% over the previous year. The medical and aesthetic business has maintained steady development. The Group's medical and aesthetic sector continues to benefit from the steady growth of the core product Lotivo® and the continued release of regenerative medical and aesthetic products and functional medical and aesthetic products, driving related business revenue growth, and the medical and aesthetic business continues to be an important source of profit for the Group. Revenue from innovative drugs and other pharmaceuticals was approximately RMB 261 million, up about 349.1% year over year. The commercialization process of the innovative drug business continues to advance. The commercialization and internationalization of various approved products progressed well, and consolidated revenue ushered in a significant increase. Compared with the net loss of the previous period, net profit for the current period increased slightly.